Reliable predictions to anticipate risks. Interlinked data to find new targets and design novel drugs. Real-world evidence to evaluate success. These capabilities eliminate the uncertainties that limit drug development but are data-intensive and experimentally inaccessible.
Molecular Health Dataome Technology offers powerful solutions to transform drug development. By merging world-class biomedical data, AI-powered analytics, and subject matter expertise, we deliver insights that go beyond human and experimental limitations.
Accelerate drug development and reduce costs by exploring in depth the complete data and information landscape around your product.
• Understand the biology of complex disease and identify better target-disease relationships
• Investigate molecular disease subtypes to identify and address responder patient populations
• Reveal new promising targets for the development of novel therapies
• Augment the value of pipeline drug candidates and portfolio drugs
• Optimize clinical trial structure, size, and relevant study cohorts
• Anticipate risks and mitigate failure of candidates at clinical stage
Eliminate bottlenecks in drug development and create new opportunities to expand the uses of
approved drugs or drug candidates.
Through proprietary text-mining and integration of data from multiple global sources, Dataome Technology assimilates and structures an unparalleled body of information that is then organized into a highly interconnected knowledgebase of expert-curated quality. Those data can then be interrogated via a unique portfolio of analytical technologies and AI methods.
Proprietary data capture and structure creates an unmatched and evolving knowledge base
In-house curation by biomedical experts to link and deliver otherwise inaccessible data
Stringent data quality assurance via highly standardized data capture and assimilation
Tailored design of in silico disease models to connect drug therapies to patient outcomes
Disease agnostic knowledge base with in-depth focus on CNS diseases and oncology
Access to real-world data from millions of patients to generate and validate relevant hypotheses
An extended, powerful portfolio of advanced analytical and AI technologies
Extensive quality certifications and medical device approval
Proven and published [1–3] track record of successful projects with industry, academia and regulators
Every project is unique. With flexible technology and an agile team, our partnership fits to your vision.
Leverage Dataome Technology to answer project-specific clinical and scientific questions.
Engage via a custom licensing agreement to jointly develop new drugs, new disease models, new clinical trials and the ensuing novel intellectual property.
License or buy out targets as well as programs after careful assessment using Dataome Technology.
 Nat Rev Clin Oncol. 2011; 8:735. PMID 21989071
 Clin Pharmacol Ther. 2021; 109:1232. PMID: 33090463
 Cancer Cell. 2015 Nov 9;28(5):610-22. PMID: 26481148
© 2022 Molecular Health GmbH
© 2020 Molecular Health GmbH